Latest Breaking News On - December american society - Page 1 : comparemela.com

Biopharmaceutical Stocks: The Next Leg Of The Rally May Begin Soon

Biopharmaceutical Stocks: The Next Leg Of The Rally May Begin Soon
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesAmerican society for hematologyRelative strength ratingBusiness dailyDecember american society

Updated MajesTEC-1 Results Continue to Show Teclistamab s Promise

Vinay Prasad, MD, leads the roundtable discussion with Aaron Goodman, MD, and Manni Mohyuddin, MD

Salt lake cityUnited statesUniversity of utahVinay prasadMark lythgoeAaron goodmanGreg laubManni mohyuddinAmerican society of hematologyUniversity of california san diegoUniversity of california san franciscoDecember american societyPage todayCalifornia san franciscoCalifornia san diegoSenior director

Selinexor OK d for Myeloma, But Does That Make It a Good Drug?

Following is a transcript of their remarks: Vinay Prasad, MD: I m back with Aaron Goodman and Dr. Al-Ola Abdallah and we re talking about selinexor. Aaron, selinexor, good drug or great drug? How would you characterize this drug? Aaron Goodman, MD: I would characterize it as an awful drug. Prasad: Awful drug? Prasad: And why is that, sir? Goodman: Well, $2,200 to $4,000 a month, so it s clearly not cheap, yet to date there is no data that it makes the patients live longer and the toxicity profile, I would say, is not favorable. The drug company would like to remind us that it does have a novel mechanism. That s about it to me.

United statesVinay prasadAl ola abdallahAaron goodmanGreg laubAmerican society of hematologyDecember american societyPage todayEarly transplantMultiple myeloma expertsOla abdallahMedpage todayProduction managerஒன்றுபட்டது மாநிலங்களில்வினய் பிரசாத்அல் ஓல அப்டால்லாஹ்

Pegcetacoplan Bests Eculizumab for PNH Patients

email article Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with paroxysmal nocturnal hemoglobinuria (PNH) who were still anemic despite at least three months of eculizumab therapy. The data were presented at December s In this exclusive MedPage Today video, study co-author Ilene C. Weitz, MD, of Keck School of Medicine at the University of Southern California, discusses the trial s findings. Following is a transcript of her remarks: The PEGASUS study was a study designed to look at the effect of C3 inhibition versus C5 inhibition in patients with PNH who were already on C5 inhibition, but had a suboptimal response. Most of these patients were transfusion dependent and had hemoglobin

Ilenec weitzGreg laubAmerican society of hematologyKeck school of medicineUniversity of southern californiaDecember american societyMedpage todayKeck schoolSouthern californiaProduction managerகிரெக் லொஉப்அமெரிக்கன் சமூகம் ஆஃப் ஹீமாட்டாலஜிகேக்க் பள்ளி ஆஃப் மருந்துபல்கலைக்கழகம் ஆஃப் தெற்கு கலிஃபோர்னியாடிசம்பர் அமெரிக்கன் சமூகம்கேக்க் பள்ளி

Early Transplant or Delayed? Multiple Myeloma Experts Debate

Following is a transcript of their remarks: Vinay Prasad, MD: All right, I m Dr. Vinay Prasad. I m an associate professor and a practicing hematologist oncologist here at the University of California San Francisco. I m joined via Zoom by two dear colleagues who are myeloma experts, Aaron Goodman, assistant professor at the University of California San Diego, an expert in bone marrow transplantation and hem malignancies, and Dr. Al-Ola Abdallah at the University of Kansas, also an expert in hematologic malignancies and bone marrow transplant. It s a pleasure to have you both here, sirs. Well, let s get started. There is so much to talk about at this year s ASH annual meeting about myeloma. All our favorite drugs are there and some of the ones we don t like too much, and so let s get started.

Vinay prasadAl ola abdallahAaron goodmanGreg laubUniversity of kansasAmerican society of hematologyUniversity of california san diegoUniversity of california san franciscoDecember american societyPage todayCalifornia sanCalifornia san diegoOla abdallahMedpage todayProduction managerவினய் பிரசாத்